News und Analysen
Agilent Presents Solutions Innovation Research Awards to Aarhus University, University of Graz, and Imperial College London Scientists
Agilent Technologies Inc. (NYSE: A) today announced Solutions Innovation Research Awards (SIRA) have been presented to Professor Anders Bentien of Aarhus University, Professor Walter Gössler of
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination
EQS-News: Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous
Sonova announces changes to its Board of Directors
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical
Humana Earns Equality 100 Award in Human Rights Campaign Foundation’s 2025 Corporate Equality Index
Leading health insurer and health care services company Humana Inc. (NYSE: HUM), has earned a score of 100 on the Human Rights Campaign Foundation (HRCF) Corporate Equality Index (CEI) for the 11th
Chemed Corporation to Present at the 43rd Annual JPMorgan Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 43rd Annual JPMorgan Healthcare Conference on Tuesday, January 14, 2024, at approximately 10:30 a.m. PST at
Acadia Healthcare to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco
Premier, Inc. to Participate in J.P. Morgan Healthcare Conference on January 14, 2025
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the J.P. Morgan Healthcare
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.
The live presentation